The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Ustekinumab is a human interleukin-12 and -23 ... and a 130mg/26mL single-dose vial for intravenous (IV) infusion. According to Sandoz, the product has extended stability and can be re ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi ...
Celltrion launches Steqeyma autoimmune treatment in U.S. market Celltrion unveils its competitive approach for Steqeyma in ...
single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. Otulfi (ustekinumab-aauz ...
Pharmaceutical Technology on MSN3d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJ&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in ...
Ustekinumab is a human monoclonal antibody that ... for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion. Otulfi ® in a 45 mg/0.5 mL single-dose vial for subcutaneous ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback